1. Long-Term Outcomes of Alemtuzumab-Based Reduced-Intensity Conditioned Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Secondary to Myelodysplastic Syndrome 
Victoria T. Potter, Pramila Krishnamurthy, Linda D. Barber, ZiYi Lim, Michelle Kenyon, Robin M. Ireland, Hugues de Lavallade, Abdel Dhouri, Judith C.W. Marsh, Robert Marcus, Stephen Devereux, Aloysius Ho, Antonio Pagliuca, Ghulam J. Mufti 
Biology of Blood and Marrow Transplantation 
Volume 20, Issue 1, Pages (January 2014)
DOI: /j.bbmt
Copyright © Terms and Conditions

2. Figure 1
(A) 5-yr OS for 192 patients receiving FBC RIC-HSCT. (B) 5-yr EFS for 192 patients receiving FBC RIC-HSCT. (C) 5-yr relapse rate for 192 patients receiving FBC RIC-HSCT. (D) 5-yr NRM for 192 patients receiving FBC RIC-HSCT.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © Terms and Conditions

3. Figure 2 (A) Effect of age on 5-yr OS. (B) Effect of age on 5-yr EFS.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © Terms and Conditions

4. Figure 3 5-yr OS according to disease category.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © Terms and Conditions